Physician profile
Matthew David Middler
NPI 1558914978
$1,135.66
in general payments reported to CMS, 2019-2025
19 companies · $824 in 2025
The $824 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $312 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,135.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $276.83 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $163.79 | 2024-2025 | Caplyta |
| Novo Nordisk INC | $117.34 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Boston Scientific Corporation | $101.94 | 2024-2025 | Wavewriter Alpha Prime 16, Watchman Access System |
| Janssen Pharmaceuticals, INC | $90.51 | 2024-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $81.59 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $53.08 | 2024 | Trelegy Ellipta, Arexvy |
| Axsome Therapeutics, INC. | $27.54 | 2025 | Auvelity |
| Inspire Medical Systems, INC. | $26.82 | 2024 | Inspire |
| Astrazeneca Pharmaceuticals LP | $24.32 | 2025 | Farxiga |
| Phathom Pharmaceuticals, INC. | $22.67 | 2024-2025 | Voquezna |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.50 | 2024 | |
| Novartis Pharmaceuticals Corporation | $20.49 | 2025 | |
| Cequr Corporation | $19.61 | 2025 | Cequr Simplicity |
| Vertex Pharmaceuticals Incorporated | $19.58 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $19.58 | 2025 | |
| Sanofi-Aventis U.S. LLC | $19.01 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.20 | 2025 | |
| Astellas Pharma US INC | $13.26 | 2024 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Middler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.